Subgroup analyses from READY: Real-world data from an Italian compassionate use program (CUP) of avelumab first-line maintenance (1LM) treatment for locally advanced or metastatic urothelial carcinoma (la/mUC)

被引：2
|
作者：
Bracarda, Sergio [1 ]
Antonuzzo, Lorenzo [2 ]
Maruzzo, Marco [3 ]
Santini, Daniele [4 ]
Tambaro, Rosa [5 ]
Buti, Sebastiano [6 ]
Carrozza, Francesco [7 ,8 ]
Calabro, Fabio
Di Lorenzo, Giuseppe [9 ]
Fornarini, Giuseppe [10 ]
Iacovelli, Roberto [11 ]
Cullura, Daniela [12 ]
Messina, Carlo [13 ]
Cerbone, Linda [14 ]
Fazzi, Gennaro [15 ]
Venturini, Filippo [15 ]
Colasanto, Raffaele [15 ]
Necchi, Andrea [16 ]
De Giorgi, Ugo [17 ]
机构：
[1] Azienda Osped Santa Maria, Terni, Italy
[2] Azienda Osped Univ Careggi, Florence, Italy
[3] IOV IRCCS, Ist Oncol Veneto, Padua, Italy
[4] Univ Sapienza Polo Pontino, Rome, Italy
[5] Ist Nazl Tumori IRCCS Fdn G Pascale, Naples, Italy
[6] Univ Parma, Parma, Italy
[7] AUSL Romagna, Ravenna, Italy
[8] IFO Ist Regina Elena, Rome, Italy
[9] ASL SALERNO PO A Tortora, Pagani, Italy
[10] IRCCS Osped Policlin San Martino, Genoa, Italy
[11] Fdn Policlin Univ A Gemelli IRCCS, Rome, Italy
[12] Ist Europeo Oncol IEO, Milan, Italy
[13] Osped ARNAS Civ, Palermo, Italy
[14] Azienda Osped San Camillo Forlanini, Rome, Italy
[15] Merck Serono SPA, Merck KGaA, Rome, Italy
[16] IRCCS San Raffaele Hosp & Sci Inst, Milan, Italy
[17] IRCCS, Ist Romagnolo Studio Tumori IRST Dino Amadori, Meldola, Italy
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 4_SUPPL期
关键词：
D O I：
10.1200/JCO.2024.42.4_suppl.558
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：558 / 558
页数：1
相关论文
共 50 条
  • [1] READY: Real-world data from an Italian compassionate use program of avelumab first-line maintenance (1LM) treatment for locally advanced or metastatic urothelial carcinoma (la/ mUC).
    Antonuzzo, Lorenzo
    Maruzzo, Marco
    De Giorgi, Ugo
    Santini, Daniele
    Tambaro, Rosa
    Buti, Sebastiano
    Carrozza, Francesco
    Calabro, Fabio
    Di Lorenzo, Giuseppe
    Fornarini, Giuseppe
    Iacovelli, Roberto
    Cullura, Daniela
    Messina, Carlo
    Masi, Claudia
    Ciccia, Angelo
    Fazzi, Gennaro
    Venturini, Filippo
    Colasanto, Raffaele
    Necchi, Andrea
    Bracarda, Sergio
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41
  • [2] Avelumab first-line maintenance (1LM) for locally advanced or metastatic urothelial carcinoma (la/mUC): Treatment (tx) patterns and real-world (rw) outcomes in the US
    Carson, K.
    Mahmoudpour, H.
    Ike, C.
    Monzon, S.
    Fragkogianni, S.
    Ferrer, J.
    Kearney, M.
    ANNALS OF ONCOLOGY, 2023, 34 : S1215 - S1216
  • [3] Avelumab first-line maintenance (1LM) in patients (pts) with locally advanced or metastatic urothelial carcinoma (la/mUC) in the Czech Republic: Interim real-world results from a national reimbursement registry.
    Zemankova, Anezka
    Studentova, Hana
    Melichar, Bohuslav
    Eid, Michal
    Poprach, Alexandr
    Kopecky, Jindrich
    Spacek, Jan
    Stuhlova, Sarka
    Dvorak, Jan
    Vlcek, Pavel
    Zychackova, Katerina
    Katolicka, Jana
    Blazek, Tomas
    Vrana, David
    Majkova, Petra
    Cepa, Adam
    Fiala, Ondrej
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (4_SUPPL) : 557 - 557
  • [4] Real-world (rw) treatment patterns, sequencing, and outcomes in patients (pts) with locally advanced or metastatic urothelial carcinoma (la/mUC) receiving avelumab first-line maintenance (1LM) in the US.
    Moon, Helen H.
    Kearney, Mairead
    Mahmoudpour, Seyed Hamidreza
    Ike, Chiemeka
    Morris, Valerie A.
    Rava, Andrew
    Kim, Sonia
    Sun, Haiyan
    Boyd, Marley
    Rey, Gabriel Gomez
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (4_SUPPL) : 605 - 605
  • [5] Real-world (rw) treatment (tx) patterns, sequencing, and outcomes in US patients (pts) with locally advanced or metastatic urothelial cancer (la/mUC) treated with avelumab first-line maintenance (1LM)
    Carson, Kenneth Robert
    Ike, Chiemeka
    Mahmoudpour, Seyed Hamidreza
    Monzon, Sebastian
    Fragkogianni, Stamatina
    Kearney, Mairead
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [6] Baseline characteristics from a retrospective, observational, US-based, multicenter, real-world (RW) study of avelumab first-line maintenance (1LM) in locally advanced/metastatic urothelial carcinoma (la/mUC) (PATRIOT-II).
    Grivas, Petros
    Barata, Pedro C.
    Moon, Helen
    Hutson, Thomas E.
    Gupta, Shilpa
    Sternberg, Cora N.
    Dave, Vaidehi
    Downey, Chad
    Shillington, Alicia C.
    Devgan, Geeta
    Kirker, Melissa
    Thakkar, Sheena
    Katzenstein, Howard M.
    Bhanegaonkar, Abhijeet
    Liu, Frank
    Brown, Jason
    Sonpavde, Guru P.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41
  • [7] Avelumab first-line maintenance treatment in patients with locally advanced or metastatic urothelial carcinoma: real-world results from a Korean expanded access program
    Park, Se Hoon
    Shin, Sang Joon
    Rha, Sun Young
    Beom, Seung-Hoon
    Seo, Ho Kyung
    Keam, Bhumsuk
    Kim, Miso
    Hong, Yoon-Hee
    Yoon, Shinkyo
    Lee, Jae-Lyun
    FRONTIERS IN ONCOLOGY, 2024, 14
  • [8] AVENANCE: Subgroup analysis of patients (pts) with advanced urothelial carcinoma (aUC) with histological variants from a real-world (RW) study of avelumab first-line maintenance (1LM)
    Barthelemy, P.
    Loriot, Y.
    Flechon, A.
    Goupil, M. Gross
    Voog, E.
    Eymard, J-C.
    Lorgis, V.
    Pouessel, D.
    Francois, L.
    Sajous, C.
    Bouju, D. Chocteau
    Guillot, A.
    Long, J.
    Amela, E.
    Josse, C.
    Solbes, M-N.
    Lambert, P.
    Thibault, C.
    ANNALS OF ONCOLOGY, 2023, 34 : S1211 - S1212
  • [9] Interim analysis (IA) of SPADE: A prospective, real-world study of avelumab first-line maintenance (1LM) treatment in patients (pts) with locally advanced or metastatic urothelial carcinoma (la/mUC) in the Asia-Pacific (APAC) region
    Park, S. H.
    Jo, J.
    Kim, M.
    Shin, S. J.
    Kim, I-H.
    Huang, Y-H.
    Tsai, Y-C.
    Oliveira, N.
    Rajappa, S. J.
    Wang, Y.
    Hoffman, J.
    Su, P. J.
    ANNALS OF ONCOLOGY, 2024, 35 : S1508 - S1509
  • [10] Updated results from AVENANCE: Real-world effectiveness of avelumab first-line maintenance (1LM) in patients (pts) with advanced urothelial carcinoma (aUC) and analysis of subsequent treatment.
    Barthelemy, Philippe
    Loriot, Yohann
    Thibault, Constance
    Gross-Goupil, Marine
    Eymard, Jean Christophe
    Voog, Eric
    Abraham Jaillon, Christine
    Le Moulec, Sylvestre
    Chasseray, Matthieu
    Gobert, Aurelien
    Auberger, Benjamin
    Viala, Caroline
    Cabart, Mathilde
    Kazan, Eyad
    Lorgis, Veronique
    Hilgers, Werner
    Josse, Constant
    Lambert, Prisca
    Solbes, Marie-Noelle
    Flechon, Aude
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (4_SUPPL) : 561 - 561
12345